Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Dealing with Melanoma Overdiagnosis - Can We Find an Off-Ramp?
Description
The presentation discusses the issue of melanoma overdiagnosis, indicating that the rise in diagnoses without a corresponding increase in mortality signifies a critical problem, similar to overdiagnosis seen in other cancers like prostate and breast cancer. The speaker highlights that unnecessary treatments result from overdiagnosis, which raises ethical concerns, especially when patients are not fully informed. It stresses the complexity of addressing overdiagnosis at the individual patient level and advocates for better clinician and patient education alongside systemic changes to reduce practices like defensive medicine. Two main assumptions about melanoma detection are challenged: firstly, the belief that early detection prevents deaths, and secondly, the assumption that prognostic tools can accurately identify risk levels among pigmented lesions. The speaker argues that reliance on a simplistic benign-malignant categorization is inadequate for assessing risk in ambiguous cases. Recommendations include emphasizing evidence-based practices, acknowledging diagnostic limitations, and changing public messages around screening efficacy. The presentation concludes by urging the dermatological community to recognize these challenges and to take steps towards addressing the overdiagnosis of melanoma through improved understanding and communication.
View moreConclusions
- The increase in melanoma diagnoses without a rise in mortality suggests significant overdiagnosis is occurring.
- Overdiagnosis results in unnecessary treatments and harmful consequences for patients.
- Patients are often unaware of the potential for overdiagnosis, raising ethical concerns.
- There is a discordance between population-level observations of overdiagnosis and individual patient interactions.
- A nuanced approach is required, balancing early detection benefits against the harms of overdiagnosis through education and systemic changes.
- Long-term clinical trials for melanoma screening and diagnostic criteria improvements are needed but currently lacking.
- Early detection strategies have failed to reduce melanoma mortality, especially among low-risk populations.
- Better prognostic tools have not materialized to effectively distinguish between dangerous and benign lesions, leading to misclassification.
- Clinicians and patients must understand the inherent uncertainties in cancer predictions and diagnostic processes.
- The current belief in increased scrutiny and early diagnosis as necessary for saving lives lacks robust evidence and should be met with skepticism.
- Mayo Clin Proc 1997; 72:559-564
- E.P. VAN DER ESCH1,18, C.S. MUIR2,19, J. NECTOUX2, G. MACFARLANE2, P. MAISONNEUVE2, H. BHARUCHA3, J. BRIGGS4, R.A. COOKE5, A.G. DEMPSTER6, W.B. ESSEX7, P.A. HOFER8, A.F. HOOD9, P. IRONSIDE10, T.E. LARSEN11, J.H. LITTLE12, R. PHILIPPS13, R.S. PFAU9, M. PRADE14, K.M. POZHARISSKI15, F. RILKE16 and K. SCHAFLER17. Int. J. Cancer: 47, 483-490 (1991)
- Michael L. Chen, BA1; Isabella Joy de Vere Hunt, MD2; Esther M. John, PhD, MSPH3,4,5; et al. JAMA Oncol. 2022;8(5):755-759. doi:10.1001/jamaoncol.2022.0134
- Raymond L. Barnhill, MD1; David E. Elder, MBChB2; Michael W. Piepkorn, MD, PhD3,4; et al. JAMA Netw Open. 2023;6(1):e2250613. doi:10.1001/jamanetworkopen.2022.50613